Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Éric Raymond(Hôpital Paris Saint-Joseph), Nicola Fazio(European Institute of Oncology), Mustafa Khasraw(Northwestern University), Chigusa Morizane(Tokyo National Hospital), Jozef Šufliarský(Comenius University Bratislava), Paul E. Oberstein(Columbia University Irving Medical Center), Matthew H. Kulke(Moffitt Cancer Center), Paul Ruff, Jiří Tomášek(Masaryk Memorial Cancer Institute), Michael Schenker(Sorbonne Université), Reza Khosravan(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Shailesh V. Shrikhande(Homi Bhabha National Institute), Espen Thiis‐Evensen(Oslo University Hospital), Shukui Qin(81th Hospital of PLA), Eva Sedláčková, Gazala Khan(Henry Ford Health System), Pascal Hammel(Hôpital Paul-Brousse), Salvatore Galdy(European Institute of Oncology), Lin Shen(Peking University), Tetsuhide Ito, Xianjun Yu(Fudan University Shanghai Cancer Center), Jian-Ming Xu(Academy of Military Medical Sciences), Yali Shen(Sichuan University), Wenhui Lou(Shanghai Medical College of Fudan University), Liqun Jia(Beijing Children’s Hospital), Adina Croitoru(Institutul Clinic Fundeni), Antonio Cubillo(Hospital Universitario HM Sanchinarro), Kathrine C. Fernandez(Pfizer (United States)), Ivan Borbath
Cited by 55
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k